Welcome to our dedicated page for Canntab Therapeutics news (Ticker: CTABF), a resource for investors and traders seeking the latest updates and insights on Canntab Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Canntab Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Canntab Therapeutics's position in the market.
Canntab Therapeutics Limited (OTCQB: CTABF) announced a binding asset purchase agreement to acquire cannabis-processing equipment and leasehold improvements from CMAX Technologies for $1,018,000. The purchase will be completed through the issuance of 1,996,078 common shares at a deemed price of $0.51 per share. Additionally, Canntab will acquire equipment from Pharmagenerics Solutions for $300,000, satisfied with 588,235 shares at the same price. Both transactions involve related parties and are subject to customary closing conditions.
Canntab Therapeutics Limited (OTCQB: CTABF) announced the appointment of Larry Latowsky as CEO, effective immediately. Latowsky, who has extensive experience in the pharmaceutical industry, was previously an Advisor to the Company. The board unanimously determined his leadership is essential for driving growth, particularly in sales and marketing. Co-founder Jeff Renwick will transition to President, continuing as a board member. Canntab specializes in hard pill cannabinoid formulations and holds multiple licenses from Health Canada, positioning itself for growth in Canada and the U.S.